196 related articles for article (PubMed ID: 34046625)
1. Discovery of novel JAK2 and EGFR inhibitors from a series of thiazole-based chalcone derivatives.
Sanachai K; Aiebchun T; Mahalapbutr P; Seetaha S; Tabtimmai L; Maitarad P; Xenikakis I; Geronikaki A; Choowongkomon K; Rungrotmongkol T
RSC Med Chem; 2021 Mar; 12(3):430-438. PubMed ID: 34046625
[TBL] [Abstract][Full Text] [Related]
2. In Silico and In Vitro Study of Janus Kinases Inhibitors from Naphthoquinones.
Sanachai K; Mahalapbutr P; Tabtimmai L; Seetaha S; Kaekratoke N; Chamni S; Azam SS; Choowongkomon K; Rungrotmongkol T
Molecules; 2023 Jan; 28(2):. PubMed ID: 36677654
[TBL] [Abstract][Full Text] [Related]
3. Exploring the interaction between epidermal growth factor receptor tyrosine kinase and some of the synthesized inhibitors using combination of
Nasab RR; Mansourian M; Hassanzadeh F; Shahlaei M
Res Pharm Sci; 2018 Dec; 13(6):509-522. PubMed ID: 30607149
[TBL] [Abstract][Full Text] [Related]
4. Biological Evaluation and Molecular Dynamics Simulation of Chalcone Derivatives as Epidermal Growth Factor-Tyrosine Kinase Inhibitors.
Sangpheak K; Tabtimmai L; Seetaha S; Rungnim C; Chavasiri W; Wolschann P; Choowongkomon K; Rungrotmongkol T
Molecules; 2019 Mar; 24(6):. PubMed ID: 30897725
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Benzamide-Chalcone Derivatives as EGFR/CDK2 Inhibitor: Synthesis, In-Vitro Inhibition, and Molecular Modeling Studies.
Joshi A; Bhojwani H; Wagal O; Begwani K; Joshi U; Sathaye S; Kanchan D
Anticancer Agents Med Chem; 2022; 22(2):328-343. PubMed ID: 33858315
[TBL] [Abstract][Full Text] [Related]
6. Discovery of JAK2/3 Inhibitors from Quinoxalinone-Containing Compounds.
Sanachai K; Mahalapbutr P; Tabtimmai L; Seetaha S; Kittikool T; Yotphan S; Choowongkomon K; Rungrotmongkol T
ACS Omega; 2022 Sep; 7(37):33587-33598. PubMed ID: 36157733
[TBL] [Abstract][Full Text] [Related]
7. Sulfonylated Indeno[1,2-
Hengphasatporn K; Aiebchun T; Mahalapbutr P; Auepattanapong A; Khaikate O; Choowongkomon K; Kuhakarn C; Meesin J; Shigeta Y; Rungrotmongkol T
ACS Omega; 2023 Jun; 8(22):19645-19655. PubMed ID: 37305292
[TBL] [Abstract][Full Text] [Related]
8. Structure-Based Drug Design Studies Toward the Discovery of Novel Chalcone Derivatives as Potential Epidermal Growth Factor Receptor (EGFR) Inhibitors.
Al-Anazi M; Al-Najjar BO; Khairuddean M
Molecules; 2018 Dec; 23(12):. PubMed ID: 30563058
[TBL] [Abstract][Full Text] [Related]
9. JAK3 inhibitor VI is a mutant specific inhibitor for epidermal growth factor receptor with the gatekeeper mutation T790M.
Nishiya N; Sakamoto Y; Oku Y; Nonaka T; Uehara Y
World J Biol Chem; 2015 Nov; 6(4):409-18. PubMed ID: 26629323
[TBL] [Abstract][Full Text] [Related]
10. Enhancing specificity in the Janus kinases: a study on the thienopyridine JAK2 selective mechanism combined molecular dynamics simulation.
Li JJ; Cheng P; Tu J; Zhai HL; Zhang XY
Mol Biosyst; 2016 Feb; 12(2):575-87. PubMed ID: 26687880
[TBL] [Abstract][Full Text] [Related]
11. Discovery of furopyridine-based compounds as novel inhibitors of Janus kinase 2: In silico and in vitro studies.
Suriya U; Mahalapbutr P; Geronikaki A; Kartsev V; Zubenko A; Divaeva L; Chekrisheva V; Petrou A; Oopkaew L; Somngam P; Choowongkomon K; Rungrotmongkol T
Int J Biol Macromol; 2024 Mar; 260(Pt 2):129308. PubMed ID: 38218283
[TBL] [Abstract][Full Text] [Related]
12. A New Series of Antileukemic Agents: Design, Synthesis, In Vitro and In Silico Evaluation of Thiazole-Based ABL1 Kinase Inhibitors.
Zeytün E; Altıntop MD; Sever B; Özdemir A; Ellakwa DE; Ocak Z; Ciftci HI; Otsuka M; Fujita M; Radwan MO
Anticancer Agents Med Chem; 2021; 21(9):1099-1109. PubMed ID: 32838725
[TBL] [Abstract][Full Text] [Related]
13. Design, Synthesis and Molecular Docking of Novel Quinazolinone Hydrazide Derivatives as EGFR Inhibitors.
Fang ZY; Zhang YH; Chen CH; Zheng Q; Lv PC; Ni LQ; Sun J; Wu YF
Chem Biodivers; 2022 Jun; 19(6):e202200189. PubMed ID: 35510593
[TBL] [Abstract][Full Text] [Related]
14. Molecular Docking and In Vitro Anticancer Screening of Synthesized Arylthiazole linked 2H-indol-2-one Derivatives as VEGFR-2 Kinase Inhibitors.
Shalmali N; Bawa S; Ali MR; Kalra S; Kumar R; Zeya B; Rizvi MA; Partap S; Husain A
Anticancer Agents Med Chem; 2022; 22(11):2166-2180. PubMed ID: 34792005
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis,
Matada GSP; Abbas N; Dhiwar PS; Basu R; Devasahayam G
Anticancer Agents Med Chem; 2021; 21(4):451-461. PubMed ID: 32698735
[TBL] [Abstract][Full Text] [Related]
16. Design, Synthesis, Molecular Docking, and Anticancer Evaluation of Pyrazole Linked Pyrazoline Derivatives with Carbothioamide Tail as EGFR Kinase Inhibitors.
Nawaz F; Alam O; Perwez A; Rizvi MA; Naim MJ; Siddiqui N; Firdaus JU; Rahman S; Jha M; Sheikh AA
Anticancer Agents Med Chem; 2021; 21(1):42-60. PubMed ID: 32718297
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Novel EGFR Inhibitor Targeting Wild-Type and Mutant Forms of EGFR: In Silico and In Vitro Study.
Todsaporn D; Zubenko A; Kartsev V; Aiebchun T; Mahalapbutr P; Petrou A; Geronikaki A; Divaeva L; Chekrisheva V; Yildiz I; Choowongkomon K; Rungrotmongkol T
Molecules; 2023 Mar; 28(7):. PubMed ID: 37049777
[TBL] [Abstract][Full Text] [Related]
18. Virtual screening and synthesis of quinazolines as novel JAK2 inhibitors.
Yang SH; Khadka DB; Cho SH; Ju HK; Lee KY; Han HJ; Lee KT; Cho WJ
Bioorg Med Chem; 2011 Jan; 19(2):968-77. PubMed ID: 21185195
[TBL] [Abstract][Full Text] [Related]
19. In silico screening of chalcone derivatives as promising EGFR-TK inhibitors for the clinical treatment of cancer.
Mathpal S; Joshi T; Sharma P; Maiti P; Nand M; Pande V; Chandra S
3 Biotech; 2024 Jan; 14(1):18. PubMed ID: 38130684
[TBL] [Abstract][Full Text] [Related]
20. New thiazole-based derivatives as EGFR/HER2 and DHFR inhibitors: Synthesis, molecular modeling simulations and anticancer activity.
Sabry MA; Ghaly MA; Maarouf AR; El-Subbagh HI
Eur J Med Chem; 2022 Nov; 241():114661. PubMed ID: 35964425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
